Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 16, 2026
DataAggregated Company Financials
Companies65
  • 7D0.3%
  • 3M6.5%
  • 1Y8.8%
  • YTD-13.9%

The Life Sciences industry has stayed flat over the last week. The past year has been better, since the industry has gained 8.8% in that time. Looking forward, earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 16 Jun 2026US$581.0bUS$150.6bUS$13.7b39.3x42.4x3.9x
Thu, 14 May 2026US$543.9bUS$150.3bUS$14.0b32x38.8x3.6x
Sat, 11 Apr 2026US$566.8bUS$147.8bUS$14.1b37.3x40.2x3.8x
Mon, 09 Mar 2026US$568.9bUS$147.8bUS$14.0b34.3x40.7x3.8x
Wed, 04 Feb 2026US$657.8bUS$147.0bUS$12.6b34.8x52.2x4.5x
Fri, 02 Jan 2026US$658.5bUS$145.8bUS$12.4b35.7x53.3x4.5x
Sun, 30 Nov 2025US$678.1bUS$145.8bUS$12.5b37x54.4x4.7x
Tue, 28 Oct 2025US$664.2bUS$145.3bUS$14.5b34.1x46x4.6x
Thu, 25 Sep 2025US$564.6bUS$144.3bUS$14.6b30.1x38.8x3.9x
Sat, 23 Aug 2025US$573.7bUS$144.1bUS$14.5b29.6x39.6x4x
Mon, 21 Jul 2025US$520.4bUS$142.9bUS$9.1b34.3x57x3.6x
Wed, 18 Jun 2025US$531.1bUS$142.9bUS$9.2b35.4x57.9x3.7x
Fri, 16 May 2025US$505.8bUS$142.7bUS$9.0b34.2x55.9x3.5x
Sun, 13 Apr 2025US$514.0bUS$142.6bUS$10.0b34.6x51.6x3.6x
Tue, 11 Mar 2025US$611.4bUS$143.1bUS$9.8b43x62.7x4.3x
Thu, 06 Feb 2025US$673.0bUS$143.1bUS$10.4b39.5x64.7x4.7x
Sat, 04 Jan 2025US$651.8bUS$142.4bUS$10.2b43.1x63.9x4.6x
Mon, 02 Dec 2024US$672.6bUS$142.4bUS$10.2b44.5x65.7x4.7x
Wed, 30 Oct 2024US$677.0bUS$142.0bUS$8.3b36.9x81.9x4.8x
Fri, 27 Sep 2024US$727.0bUS$141.8bUS$8.5b38x85.5x5.1x
Sun, 25 Aug 2024US$743.2bUS$141.8bUS$8.5b37.4x87.8x5.2x
Tue, 23 Jul 2024US$675.6bUS$141.2bUS$12.2b40.7x55.3x4.8x
Thu, 20 Jun 2024US$696.9bUS$141.3bUS$12.2b38.6x57.2x4.9x
Sat, 18 May 2024US$742.9bUS$141.5bUS$12.5b38.3x59.4x5.3x
Mon, 15 Apr 2024US$711.1bUS$142.0bUS$12.8b42.3x55.6x5x
Wed, 13 Mar 2024US$753.3bUS$142.1bUS$12.9b44.6x58.5x5.3x
Fri, 09 Feb 2024US$709.3bUS$141.9bUS$12.8b39.1x55.6x5x
Sun, 07 Jan 2024US$684.7bUS$153.9bUS$14.2b36.1x48.3x4.5x
Tue, 05 Dec 2023US$651.8bUS$153.7bUS$14.0b35.4x46.5x4.2x
Thu, 02 Nov 2023US$572.3bUS$153.9bUS$11.1b29.2x51.3x3.7x
Sat, 30 Sep 2023US$670.3bUS$154.6bUS$11.2b33.3x59.8x4.3x
Mon, 28 Aug 2023US$712.7bUS$154.6bUS$11.2b32.9x63.6x4.6x
Wed, 26 Jul 2023US$744.0bUS$155.0bUS$12.1b29.8x61.3x4.8x
Fri, 23 Jun 2023US$691.0bUS$152.4bUS$12.5b29.2x55.3x4.5x
Price to Earnings Ratio

55.3x


Total Market Cap: US$691.0bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.3x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.4x which is lower than its 3-year average PE of 56.3x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.1% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market2.20%
Healthcare0.64%
Life Sciences0.28%
Clinical Research and Equipment0.28%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$473.720.9%
+US$1.5b		16.9%PE25.7x
ILMN IlluminaUS$166.895.6%
+US$1.3b		84.9%PE29.6x
WST West Pharmaceutical ServicesUS$331.433.7%
+US$825.2m		47.8%PE43.1x
TEM Tempus AIUS$52.327.7%
+US$669.8m		-27.3%PS6.9x
TECH Bio-TechneUS$56.176.7%
+US$551.1m		8.8%PE80.3x

Latest News

ICLR
US$147.72
ICON
7D
-3.0%
1Y
0.5%
WST
US$331.43
West Pharmaceutical Services
7D
3.7%
1Y
47.8%
ILMN
US$166.89
Illumina
7D
5.6%
1Y
84.9%
Narrative Update • Jun 15

ILMN: Future Returns Will Hinge On Clinical Sequencing Momentum And Customer Stickiness

Narrative Update: Illumina The analyst price target underpinning this Illumina narrative has been raised from about $136 to $147, reflecting updated assumptions around customer stickiness, clinical sequencing momentum, and expectations for higher instrument and consumables spending highlighted in recent research. Analyst Commentary Recent research on Illumina reflects a mix of enthusiasm about the company’s position in sequencing markets and some ongoing caution around execution and valuation, with several major firms updating ratings and price targets.
IQV
US$178.39
IQVIA Holdings
7D
-2.9%
1Y
12.0%
Narrative Update • Jun 14

IQV: AI Initiatives And B2B Demand Will Support Earnings Reacceleration

IQVIA Holdings' implied fair value has been trimmed by about $1.65 to roughly $226.95, reflecting analysts' lower price targets around $210 in response to cautious sentiment on life science tools, even as they see early signs of recovery in areas like bioprocessing and quality assurance. Analyst Commentary Recent research points to a mixed setup for IQVIA Holdings, where cautious sentiment on life science tools is bumping up against early signs of recovery in specific end markets.
RGEN
US$130.87
Repligen
7D
4.4%
1Y
3.8%
Narrative Update • Jun 13

RGEN: Bioprocess Recovery And Training Hub Expansion Will Guide Future Performance

Repligen's analyst price target has been reset slightly lower to $142, as analysts factor in a modestly higher discount rate along with still-supportive views on bioprocessing demand and the broader life science tools recovery. Analyst Commentary Recent Street research around Repligen reflects a mixed setup, with several firms trimming price targets and a few others highlighting potential recovery in bioprocessing demand.
TEM
US$52.32
Tempus AI
7D
7.7%
1Y
-27.3%
Narrative Update • Jun 13

TEM: FDA Progress And Data Platforms Will Drive Future Oncology Demand

Tempus AI's analyst price targets have shifted lower to around $66.53, reflecting a mix of downward revisions and more cautious views on long term monetization from several firms, even as others acknowledge the company's differentiated data offering. Analyst Commentary Recent research paints a mixed picture around Tempus AI, with views split on how quickly the company can translate its differentiated data assets into predictable cash flows and what that should mean for valuation.
A
US$130.59
Agilent Technologies
7D
-1.6%
1Y
9.7%
DHR
US$181.10
Danaher
7D
-1.3%
1Y
-9.9%
STVN
US$16.63
Stevanato Group
7D
-7.6%
1Y
-31.5%
Seeking Alpha • Jun 11

Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside

Summary Stevanato Group is reiterated as a Buy, driven by robust Q1 results and a compelling long-term growth trajectory. The High-Value Solutions segment accelerated, now comprising 47% of sales, fueled by broad biologics and injectable therapies demand. Management attributed the slowdown in the Engineering segment to project timing and order delays rather than competitive pressure or deteriorating demand. Importantly, segment profitability improved despite lower volumes. Margin expansion, operational leverage from new facilities, and growth are not well reflected in the current valuation. We reiterate our buy rating. Read the full article on Seeking Alpha
TXG
US$32.22
10x Genomics
7D
10.4%
1Y
192.6%
Narrative Update • Jun 11

TXG: Multiomic Expansion And Spatial Launch Plans Will Shape Fairly Valued Outlook

Analysts have lifted their price targets on 10x Genomics by a range of $2 to $10, reflecting updated views on the stock. These revisions are now feeding into this valuation narrative and refined assumptions around discount rate, revenue growth, profit margins, and future P/E.
WAT
US$357.76
Waters
7D
-1.5%
1Y
2.9%
ABCL
US$5.26
AbCellera Biologics
7D
-3.0%
1Y
66.5%
Narrative Update • Jun 10

ABCL: Menopause Phase 2 Progress Will Support Future Margin Expansion

The analyst price target on AbCellera Biologics has been raised by $1. Analysts cite updated fair value estimates, a slightly lower discount rate, revised revenue growth expectations, and a very large projected future P/E multiple as key drivers of the change.
TMO
US$473.72
Thermo Fisher Scientific
7D
0.9%
1Y
16.9%
Narrative Update • Jun 09

TMO: AI Tools And Proteomics Platforms Will Drive Future Upside

Thermo Fisher Scientific's updated fair value estimate has moved down from about $738 to $721 per share as analysts temper longer term revenue growth assumptions, partly reflecting recent price target cuts and more cautious views on organic growth momentum, even as they acknowledge that the company's margin profile and P/E remain supportive. Analyst Commentary Recent Street research paints a mixed picture for Thermo Fisher Scientific, with some analysts turning more cautious on near term organic growth while others highlight the stock as a core holding for exposure to life science tools.
TECH
US$56.17
Bio-Techne
7D
6.7%
1Y
8.8%
BIO
US$289.28
Bio-Rad Laboratories
7D
-0.7%
1Y
24.9%
Narrative Update • Jun 04

BIO: Activist Pressure And Buybacks Will Shape Future Value Realization

Analysts have reaffirmed their $320.00 price target for Bio-Rad Laboratories, citing adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the main factors behind the updated view. What's in the News Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories after the stock declined more than 70% from its late 2021 peak, and is publicly pushing for improvements in the share price and company performance.
MTD
US$1,154.47
Mettler-Toledo International
7D
1.4%
1Y
-2.4%
Narrative Update • Jun 03

MTD: Automation And Emerging Markets Will Support EPS Upside Despite Geopolitical Risks

Analysts have trimmed their average price target for Mettler-Toledo International from about $1,344.50 to roughly $1,327.83. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E expectations.